OR-LATTICE-SEMICONDUCTOR
24.6.2020 22:02:04 CEST | Business Wire | Press release
Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today launched the new Lattice Certus™-NX family of FPGAs. The devices lead the general-purpose FPGA market in I/O density, delivering up to twice the I/O density per mm2 in comparison to similar competing FPGAs, and provide best-in-class power savings, small size, reliability, instant-on performance, and support fast PCI Express (PCIe) and Gigabit Ethernet interfaces to enable data co-processing, signal bridging, and system control. Certus-NX FPGAs target a range of applications, from data processing in automated industrial equipment to system management in communications infrastructure. The Certus-NX devices are the second family of FPGAs developed on the Lattice Nexus™ platform, the industry’s first low power FPGA platform using 28 nm FD-SOI process technology. With the launch of Certus-NX, Lattice marks the release of the second device family developed under Lattice’s new product development strategy in just six months.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200624005722/en/
“Certus-NX delivers unique and innovative capabilities that set it apart,” said Linley Gwennap, Principal Analyst at The Linley Group. “Compared to competing FPGAs of similar gate counts, Lattice offers a much smaller package, greater I/O density, and lower power.”
“Thanks to innovations at the system, architecture, and circuit level in our Lattice Nexus development platform, we are releasing new products at a faster pace and giving our customers more options to choose from as they evaluate the performance and power needs of their applications,” said Gordon Hands, Director of Product Marketing, Lattice Semiconductor. “Certus-NX has clearly reset expectations for what developers should look for in general-purpose FPGAs by providing a compelling blend of parallel processing performance and flexible I/O support that enables creative new device designs.”
Technology trends like industrial automation and 5G have developers across markets looking to add processing and connectivity to applications that operate at the network Edge. To successfully support these trends, devices require low power processing hardware with support for popular interfaces like PCIe and Gigabit Ethernet. Device developers also need easy-to-use development platforms from a single source that provide the hardware, software, and IP they need to get products to market quickly.
“As an FPGA-centric design house, we’re seeing increasing adoption of serial protocols like PCIe and Gigabit Ethernet for chip-to-chip connectivity in many end applications, including 5G and IoT systems,” said Sanjeev Kumar, CEO, Logic Fruit Technologies. “The latest generation of FPGAs by Lattice, Certus-NX, supports these standards and provides a high density of I/Os while keeping power consumption and overall device footprint in check. These FPGAs will allow us to rapidly adapt to the challenging and evolving connectivity and performance needs of our customers.”
Key features of the Lattice Certus-NX FPGA family include:
- Up to 3x smaller form factor – Certus-NX FPGAs easily fit into compact designs with minimal impact on overall design footprint. For example, Certus-NX FPGAs can enable a complete PCIe solution with a size of only 36 mm2 . Even when using the smallest package available in the family, Certus-NX FPGAs deliver up to twice the I/O density per mm2 in comparison to similar competing FPGAs to enable greater design flexibility and robust support for bridging applications.
-
Robust I/O interfacing capability – Certus-NX developers will have access to Lattice’s extensive IP library. Notable IP blocks available on Certus-NX include:
- 1.5 Gbps differential I/O with performance that is up to 70 percent higher than competing FPGAs.
- 5 Gbps PCIe, 1.5 Gbps SGMII, and 1066 Mbps DDR3. Developers can test these IP blocks on Certus-NX development boards for the fast implementation of interfaces commonly used in Certus-NX FPGAs’ target applications.
-
Robust authentication and encryption – To secure the devices’ bitstream against unauthorized access/alteration/copying, Certus-NX FPGAs support AES-256 with ECDSA authentication to protect devices throughout their lifecycles. Currently, Certus-NX devices are the smallest FPGAs on the market to support ECDSA.
- Up to 4x lower power consumption – Certus-NX FPGAs use a programmable back bias to enable user-selectable high performance or low power operating modes, depending on the needs of their application. The devices can provide power consumption up to 4x lower than similar FPGAs.
- Instant-on performance – The devices also offer ultra-fast device configuration from SPI memory that is up to 12x faster than similar competing FPGAs, with individual I/Os able to configure in just 3 ms, and full-device startup in only 8-14 ms depending on device capacity.
- High reliability – Reliable performance is key for safety-critical industrial and automotive applications where devices must perform as expected to avoid damage/injury. Certus-NX FPGAs offer up to 100 times better soft-error rate (SER) performance than similar FPGAs. Certus-NX FPGAs are temperature-rated for use in industrial applications. They also support ECC and SEC in hardware.
- Ease of use/design – Certus-NX FPGAs support Lattice Radiant® software, an easy-to-use, unified FPGA design environment that integrates best-in-class tools and features to help users develop their applications quickly and efficiently.
Lattice has already shipped sample devices to select customers. For more information, please visit http://www.latticesemi.com/Certus-NX .
About Lattice Semiconductor
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing communications, computing, industrial, automotive, and consumer markets. Our technology, long-standing relationships, and commitment to world-class support lets our customers quickly and easily unleash their innovation to create a smart, secure and connected world.
For more information about Lattice, please visit www.latticesemi.com . You can also follow us via LinkedIn , Twitter , Facebook , YouTube , WeChat , Weibo or Youku .
Lattice Semiconductor Corporation, Lattice Semiconductor (& design) and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.
GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200624005722/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
